Avalo Therapeutics, Inc. 8-K

What Happened
Avalo Therapeutics, Inc. (NASDAQ: AVTX) filed a Form 8‑K on June 8, 2026, reporting that its stockholders approved the Avalo Therapeutics, Inc. Second Amended and Restated 2016 Employee Stock Purchase Plan (A&R 2016 ESPP) at the company’s 2026 annual meeting. The Board previously adopted the A&R 2016 ESPP on April 2, 2026. A full description was included in the company’s Definitive Proxy Statement filed April 10, 2026, and the amended plan is attached to the 8‑K as Exhibit 10.1.

Key Details

• Stockholder approval occurred at Avalo’s 2026 Annual Meeting (date of meeting noted in the Proxy Statement).
• Board adoption date of the A&R 2016 ESPP: April 2, 2026.
• Definitive Proxy Statement describing the plan was filed April 10, 2026.
• The A&R 2016 ESPP document is attached to the 8‑K as Exhibit 10.1.

Why It Matters
Approval of the amended ESPP allows Avalo to offer revised employee stock purchase benefits under the updated plan terms, which can affect employee equity compensation and potentially support recruitment and retention. For investors, changes to an ESPP can dilute outstanding shares over time if new shares are issued under the plan; the filing documents provide the detailed terms and any share limits that determine the magnitude of potential dilution.